Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Optic Atrophies, Hereditary
Welcome,
Profile
Billing
Logout
5 Companies
3 Products
3 Products
2 Mechanisms of Action
1 Trial
14 News
|
|||||||||
Lumevoq
(lenadogene nolparvovec) /
GenSight
Trial primary completion date:
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
(clinicaltrials.gov) - Jan 31, 2018
P=N/A
, N=9, Completed,
Sponsor: Bin Li
Trial primary completion date: May 2015 --> Nov 2015
||||||||||
Lumevoq
(lenadogene nolparvovec) /
GenSight
Trial completion, Trial primary completion date:
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
(clinicaltrials.gov) - May 19, 2015
P=N/A
, N=6, Completed,
Sponsor: Bin Li
Trial primary completion date: May 2015 --> Nov 2015 Recruiting --> Completed | Trial primary completion date: Sep 2013 --> May 2015
||||||||||
Vincerinone
(vatiquinone) /
Sumitomo Dainippon, PTC Therap
Clinical:
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
(clinicaltrials.gov) - Nov 25, 2014
P=N/A
, N=0, No Longer Available,
Sponsor: Edison Pharmaceuticals Inc
||||||||||
Catena
(idebenone) /
Santhera, Chiesi
Trial withdrawal:
Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
(clinicaltrials.gov) - Aug 22, 2014
P3
, N=0, Withdrawn,
Sponsor: Santhera Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Sep 2013 --> May 2015 Not yet recruiting --> Withdrawn
||
||||||||
Trial primary completion date:
Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey
(clinicaltrials.gov) - May 13, 2014
P=N/A
, N=306, Completed,
Sponsor: Santhera Pharmaceuticals
Not yet recruiting --> Withdrawn Trial primary completion date: Oct 2013 --> Feb 2014
|||
|||||||
Trial completion:
Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey
(clinicaltrials.gov) - May 13, 2014
P=N/A
, N=306, Completed,
Sponsor: Santhera Pharmaceuticals
Trial primary completion date: Oct 2013 --> Feb 2014 Not yet recruiting --> Completed
||||||||||
Trial termination:
Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)
(clinicaltrials.gov) - Aug 20, 2013
P1/2
, N=4, Terminated,
Sponsor: Medical College of Wisconsin
Not yet recruiting --> Completed Recruiting --> Terminated; Unable to record n95 pERG peak (primary measure), as LHON subjects are unable to focus on target.
||||||||||
Enrollment change:
Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)
(clinicaltrials.gov) - Aug 20, 2013
P1/2
, N=4, Terminated,
Sponsor: Medical College of Wisconsin
Recruiting --> Terminated; Unable to record n95 pERG peak (primary measure), as LHON subjects are unable to focus on target. N=60 --> 4
|||
|||||||
Clinical:
Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey
(clinicaltrials.gov) - Jul 4, 2013
P=N/A
, N=350, Not yet recruiting,
Sponsor: Santhera Pharmaceuticals
|
|||||||||
Trial completion:
A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)
(clinicaltrials.gov) - Dec 19, 2012
P3
, N=70, Completed,
Sponsor: Mahidol University
N=60 --> 4 Recruiting --> Completed
|
|||||||||
Catena
(idebenone) /
Santhera, Chiesi
New P3 trial:
Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
(clinicaltrials.gov) - Dec 15, 2011
P3
, N=0, Not yet recruiting,
Sponsor: Santhera Pharmaceuticals
||
||||||||
Enrollment change:
RHODOS-OFU: RHODOS Follow-up Single-visit Study
(clinicaltrials.gov) - Dec 11, 2011
P=N/A
, N=60, Completed,
Sponsor: Santhera Pharmaceuticals
Recruiting --> Completed N=85 --> 60
|||
|||||||
Trial completion:
RHODOS-OFU: RHODOS Follow-up Single-visit Study
(clinicaltrials.gov) - Dec 11, 2011
P=N/A
, N=60, Completed,
Sponsor: Santhera Pharmaceuticals
N=85 --> 60 Enrolling by invitation --> Completed
||
||||||||
Enrollment change:
Transcorneal Electrical Stimulation Therapy for Retinal Disease
(clinicaltrials.gov) - Nov 27, 2011
P=N/A
, N=80, Completed,
Sponsor: Okuvision GmbH
Enrolling by invitation --> Completed N=200 --> 80